Failures to reach treatment target in clinical practice are partly due to the fact that patients have difficulties implementing insulin therapy; a nationwide study in the United States showed that 29% of patients with T2DM treated with insulin never practiced SMBG [11]. This evidence concerns the gene INS and type 2 diabetes mellitus.